Arch Biopartners Inc
XTSX:ARCH

Watchlist Manager
Arch Biopartners Inc Logo
Arch Biopartners Inc
XTSX:ARCH
Watchlist
Price: 1.86 CAD 3.91%
Market Cap: 120.6m CAD
Have any thoughts about
Arch Biopartners Inc?
Write Note

Arch Biopartners Inc
Investor Relations

Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.

Show more

Earnings Calls

No Earnings Calls Available

Management

Mr. Richard Gabriel Muruve
Co-Founder, CEO, President & Director
No Bio Available
Dr. Daniel Abraham Muruve M.D.
Co-Founder, Chief Science Officer & Member of Scientific Advisory Board
No Bio Available
Mr. Andrew Bishop CFA
CFO & Director
No Bio Available
Dr. Paul Beck
Co-Founder & Principal Scientist
No Bio Available
Mr. Aaron Benson
Director of Communications
No Bio Available

Contacts

Address
ONTARIO
TORONTO
545 King St W
Contacts
+16474287031.0
archbiopartners.com